Albany, NY -- (SBWIRE) -- 07/29/2019 -- Neuroblastoma Market Insights, Epidemiology and Market Forecast-2028
1. Neuroblastoma total Incident population in the 7 major markets were observed to be more than 1500 in 2017.
2. Neuroblastoma incidence rate is increasing at a very slow rate in the United States, has stabilized in the EU5 and is decreasing in Japan for the forecasted period, i.e. 2017-2028.
3. Among the European countries, France has the highest Neuroblastoma Incident population with 156 cases, followed by the United Kingdom had Neuroblastoma Incident population of 147 in 2017.
DelveInsight launched a new report on Neuroblastoma Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Neuroblastoma market report covers a descriptive overview and comprehensive insight of the Neuroblastoma epidemiology and Neuroblastoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Neuroblastoma market report provides insights on the current and emerging therapies.
3. Neuroblastoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Neuroblastoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neuroblastoma market.
Request for sample pages
"The total low risk group patients of Neuroblastoma in the United Sates were assessed to be 117 in 2017, while those for intermediate and high-risk group patients were observed to be 186 and 326, respectively in 2017."
Neuroblastoma therapeutic market in the seven major markets was assessed to be USD 86.70 million in 2017. Neuroblastoma market is expected to show positive growth, mainly attributed to increased Neuroblastoma incidence. Additionally, Neuroblastoma market is also estimated to show positive growth due to the expected launch of Neuroblastoma emerging therapies during the forecast period [2019-2028].
Chemotherapy is the therapy that is usually first used for Neuroblastoma treatment, including drugs such as cyclophosphamide, cisplatin or carboplatin, vincristine, doxorubicin, etoposide, and topotecan, and are recommended before and after surgery for destroying cancer cells.
The total Chemotherapy Neuroblastoma market in the 7MM was USD 21.02 million in 2017 and will witness a significant change over the period, whereas the retinoid therapy market will not change much due to its less usage in both intermediate and high-risk groups. Among the EU-5 Countries, France has the highest Neuroblastoma market size with USD 5.79 million, followed by Italy with USD 5.48 million in 2017. In contrast, Spain has the lowest Neuroblastoma market size with sales of USD 3.36 million in 2017.
The initial step of Neuroblastoma treatment patients in low & intermediate risk groups is surgery followed by chemotherapies, radiation and retinoid therapies (Isotretinoin). Radiations & Retinoid therapies are used only in intermediate risk groups. Here, only the therapeutic Neuroblastoma market is estimated which includes all the treatments except Surgery, Radiation, and Transplantation.
The launch of the emerging therapies is expected to significantly impact Neuroblastoma treatment scenario in the upcoming years:-
Drugs covered
1. Naxitamab
2. Omburtamab
3. 131I-MIBG
4. CMD-501
5. MNX-100
6. 13-CRA
And many others
The key players in Neuroblastoma market are:
1. Y-mabs therapeutics
2. Jubilant DraxImage
3. Cell Medica,
4. Nova Laboratories Limited
5. METRONOMX
6. And many others
Table of contents
1. Key insights
2. Neuroblastoma Market overview at a glance
3. Neuroblastoma Disease background and overview
4. Neuroblastoma Epidemiology and Patient Population
5. Neuroblastoma 7MM Total Incident Patient Population
5.1. Neuroblastoma Country Wise-Epidemiology
5.1.1.The United States
5.1.2.EU5 Countries
5.1.3.Germany
5.1.4.France
5.1.5. United Kingdom
5.1.6.Spain
5.1.7.Italy
5.1.8.Japan
6. Neuroblastoma Current Treatment And Medical Practices
7. Neuroblastoma Marketed Drugs
7.1. Unituxin: United Therapeutics Corp
7.2. Qarziba: EUSA Pharma
8. Neuroblastoma Potential Pipeline Therapies
9. Neuroblastoma Pipeline Profiles
9.1. Naxitamab: Y-MABS Therapeutics Inc
9.2. Omburtamab: Y-MABS Therapeutics Inc
9.3. 131I-MIBG (Iobenguane; Jubilant DraxImage)
9.4. MNX-100: Metronomx
10. Neuroblastoma Market Analysis
11. Neuroblastoma Market Outlook 7 Major Markets
11.1. Neuroblastoma Market Size In 7MM (2017-2028)
12. Neuroblastoma United States Market Outlook
12.1. Neuroblastoma United States Market Size
13. Neuroblastoma EU-5 Market Outlook
13.1. Germany Market Size
13.2. France Market Size
13.3. Neuroblastoma United Kingdom Market Size
13.4. Spain Market Size
13.4.3. Italy Market Size
14. Neuroblastoma Japan Market Outlook
14.1. Japan Market Size
15. Market Drivers
16. Market Barriers
17. Appendix
18. Delveinsight Capabilities
19. Disclaimer
20. About Delveinsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight